

Background

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a potential treatment-related adverse event of chimeric antigen receptor (CAR) T-cell therapy with severity ranging from mild to life-threatening.¹

Methods

- Adult patients with Large B-cell lymphoma receiving CD19-directed CAR Tcell therapy, between 2022 and 2023 at the University Medical Center Groningen, were prospectively included.
- Early intervention strategies hold promise in reducing the incidence and severity of ICANS.²
- ICANS grading is based on a non-validated ICE score and clinical signs. This method lacks predictive capacity and may detect ICANS too late, leading to a high cumulative dose of steroids to reestablish ICANS.

Aim

To investigate the use of a novel EEG-based brain state monitor as a prediction tool for ICANS in patients receiving CAR T-cell therapy.

- Before and twice daily after CAR T-cell infusion, patients underwent a single channel electroencephalogram (EEG) recording (Fp2-Pz) using the DeltaScan (Prolira, The Netherlands). A score (1-5) was automatically generated.
- ICANS grade was determined according to the ASTCT consensus grading system and clinical interpretation of the ICE score was performed by the treating physician.



Results

Fifteen patients were subjected to analysis. Sixty percent of these patients

were male. The mean age was 63 (± 10) years and six (40%) patients had a localization within the central nervous system.

- Six (40%) patients experienced ICANS grade \geq 2. The average duration of ICANS in these patients was 9 (±3) days. All these patients (100%) had an elevated DeltaScan score (>3).
- In 83% of the cases, the elevated DeltaScan score was measured prior to the decline in the ICE score, specifically 13.1 (±12.2) hours in advance.

Contact





Conclusion

- Early detection of ICANS in patients undergoing CAR T-cell therapy is feasible with a single-channel EEG recording.
- Elevated DeltaScan score preceded a diminished ICE score and the occurrence of ICANS. This implies that the DeltaScan score can predict ICANS.
- The ongoing study is expanded into a multi-center study.



¹ Sterner, R. C., & Sterner, R. M. (2022). Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. Frontiers in immunology, 13, 879608. ² Topp, M. S., van Meerten, T., Houot, R., Minnema, M. C., Bouabdallah, K., Lugtenburg, P. J., Thieblemont, C., Wermke, M., Song, K. W., Avivi, I., Kuruvilla, J., Dührsen, U., Zheng, Y., Vardhanabhuti, S., Dong, J., Bot, A., Rossi, J. M., Plaks, V., Sherman, M., Kim, J. J., ... Kersten, M. J. (2021). Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. British journal of haematology, 195(3), 388-398.